NEW YORK (GenomeWeb News) – Saladax Biomedical said this week that it plans to open a CLIA lab at its headquarters in Bethlehem, Pa. The firm has applied for approval from both the State of Pennsylvania and the federal government and is targeting a launch next year.

Saladax offers MyCare tests for individualized dose management of three cancer drugs: 5-fluorouracil, paclitaxel, and docetaxel. It has another 10 MyCare tests in development, it said, and plans to offer the tests through the CLIA lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.